Cytek Biosciences/$CTKB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Ticker
$CTKB
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
663
ISIN
US23285D1090
Website
CTKB Metrics
BasicAdvanced
$389M
-
-$0.09
1.42
-
Price and volume
Market cap
$389M
Beta
1.42
52-week high
$7.30
52-week low
$2.37
Average daily volume
1.4M
Financial strength
Current ratio
5.621
Quick ratio
4.737
Long term debt to equity
2.204
Total debt to equity
2.204
Profitability
EBITDA (TTM)
-19.976
Gross margin (TTM)
54.94%
Net profit margin (TTM)
-5.71%
Operating margin (TTM)
-13.89%
Effective tax rate (TTM)
-41.14%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-3.51%
Return on equity (TTM)
-2.91%
Valuation
Price to revenue (TTM)
2.025
Price to book
1.03
Price to tangible book (TTM)
1.14
Price to free cash flow (TTM)
23.012
Free cash flow yield (TTM)
4.35%
Free cash flow per share (TTM)
13.34%
Growth
Revenue change (TTM)
-1.86%
Earnings per share change (TTM)
-0.35%
3-year revenue growth (CAGR)
12.41%
3-year earnings per share growth (CAGR)
51.23%
What the Analysts think about CTKB
Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.
Bulls say / Bears say
Cytek Biosciences' Q3 FY2024 revenue increased by 7% year-over-year, driven by strong international demand and a 25% surge in service revenue, indicating robust growth in recurring revenue streams. (seekingalpha.com)
The company announced a $50 million share repurchase program commencing January 1, 2025, reflecting management's confidence in the company's value and commitment to returning capital to shareholders. (tradingview.com)
Analyst Steven Mah of TD Cowen maintained a 'Buy' rating on Cytek Biosciences with a price target of $12.00, citing the company's potential for future revenue growth despite recent setbacks. (markets.businessinsider.com)
The Goldman Sachs Group downgraded Cytek Biosciences from a 'Buy' to a 'Sell' rating, reducing the price target from $7.00 to $4.50, indicating concerns about the company's future performance. (defenseworld.net)
In Q1 2025, Cytek reported a net loss of $11.402 million, a deeper loss compared to $6.169 million in the previous year, influenced by reduced revenue and increased operating expenses. (tradingview.com)
The company's gross margin declined from 57% to 55% year-over-year, attributed to higher material costs and a less favorable product mix, potentially impacting profitability. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CTKB Financial Performance
Revenues and expenses
CTKB Earnings Performance
Company profitability
CTKB News
AllArticlesVideos
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
GlobeNewsWire·3 weeks ago
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Cytek Biosciences Reports First Quarter 2025 Financial Results
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytek Biosciences stock?
Cytek Biosciences (CTKB) has a market cap of $389M as of June 20, 2025.
What is the P/E ratio for Cytek Biosciences stock?
The price to earnings (P/E) ratio for Cytek Biosciences (CTKB) stock is 0 as of June 20, 2025.
Does Cytek Biosciences stock pay dividends?
No, Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Cytek Biosciences dividend payment date?
Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytek Biosciences?
Cytek Biosciences (CTKB) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.